The pallido-nigro-luysian axis and nigrostriatal system serve as sensitive targets for detecting tau deposition and monoaminergic disruption in PSP and local striatal tau pathology and tau burden were associated with monoaminergic disruption in PSP.
Abstract
Purpose: Progressive supranuclear palsy (PSP) is a tauopathy marked by widespread tau aggregation and prominent monoaminergic dysfunction, yet the relationship between regional tau burden and monoaminergic impairment remains unclear. In this study, we determine whether regional tau burden is associated with nigrostriatal monoaminergic dysfunction in PSP using PET imaging. Patients and Methods: A subset of 20 patients with PSP and monoaminergic impairment, identified by 18F-FP-DTBZ PET, was recruited and subsequently underwent 18F-APN-1607 PET to assess tau deposition. All images were spatially normalized and analyzed based on predefined volumes of interest. Erosion-based cerebral white matter was used as the reference region to calculate standardized uptake value ratios (SUVRs) for 18F-APN-1607 PET. Results: The SUVRs of 18F-APN-1607 PET differed significantly between patients with PSP and healthy controls in the globus pallidus, substantia nigra, subthalamus nucleus, and red nucleus, while a significant difference in 18F-FP-DTBZ SUVRs was observed in all the striatal regions and substantia nigra. Regression analysis discovered negative associations between tau load and monoaminergic disruption in the putamen and caudate, whereas tau accumulation in the substantia nigra was not significantly associated with nigrostriatal impairment. Conclusions: The pallido-nigro-luysian axis and nigrostriatal system serve as sensitive targets for detecting tau deposition and monoaminergic disruption in PSP. Local striatal tau pathology and tau burden were associated with monoaminergic disruption in PSP.
PSP and AD showed distinct patterns of tract vulnerability associated with regional florzolotau(18F) retention and clinical impairment, and cross-sectional findings support further longitudinal investigation of disease-specific network degeneration.
Chi-Wei Huang, Hsin-I Chang, T. Chang et al.· European Journal of Nuclear...· 0 citations
Background Progressive supranuclear palsy (PSP) is a primary tauopathy defined by the accumulation of 4R tau isoforms in neurons, oligodendrocytes and astrocytes. Despite evidence of genetic susceptibility operating through glial cell types, it remains poorly understood how cell type-specific epigenetic-transcriptional...
N. Briel, Viktoria C. Ruf, Paul L. C. Feyen et al.· bioRxiv· 0 citations
BACKGROUND
Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear.
OBJECTIVES
To explore longitudinal tau accumulati...
Yoshikazu Chishiki, Kenji Tagai, Y. Kataoka et al.· Movement Disorders· 0 citations
White matter microstructural disruption is a dominant imaging signature of CBS and is more closely linked to gray matter volume loss than to measurable uptake on tau PET, while dMRI, particularly MD and ICVF, may provide greatest sensitivity for detecting disease-related changes in CBS.
Yu-Qi Tian, Ryota Satoh, V. Lowe et al.· medRxiv· 0 citations
The association between MLR and the composite Frontal Network Score supports a link between systemic immune alterations and network-level neurodegeneration in PSP.
B. Migda, M. Kutyłowski, Natalia Madetko-Alster et al.· Neurology International· 0 citations
BACKGROUND
The relative value of nigrostriatal volumetry, quantitative T1 relaxation, and multicompartment diffusion MRI in neurodegenerative Parkinson syndromes is unclear.
OBJECTIVES
To compare quantitative T1 relaxation and diffusion microstructure imaging-derived free fluid fraction (V-CSF) in the putamen and sub...
N. Schröter, Lucas A. Both, Wolfgang H. Jost et al.· Parkinsonism & Related Disor...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.